1. Strategies for drug discovery for cognitive aging and alzheimer’s disease

   • Howard M. Fillit
   • Alan W. O’Connell
   • Lorenzo M. Refolo

   Introduction Pages: 1 - 3

2. Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in alzheimer’s disease

   • Mei-Ping Kung
   • Catherine Hou
   • Hank F. Kung

   Early Detection Of Cognitive Impairment Pages: 7 - 10

3. Synthesis and evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer’s disease

   • Yanming Wang
   • William E. Klunk
   • Chester A. Mathis

   Early Detection Of Cognitive Impairment Pages: 11 - 16

4. Brain-imaging surrogate markers for detection and prevention of age-related memory loss

   • Gary W. Small

   Early Detection Of Cognitive Impairment Pages: 17 - 21

5. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial

   • Michael Grundman
   • Drahomira Sencakova
   • the Alzheimer’s Disease Cooperative Study

   Early Detection Of Cognitive Impairment Pages: 23 - 27

6. Lipid rafts play an important role in Aβ biogenesis by regulating the β-secretase pathway

   • Han Tun
   • Laura Marlow
   • Kumar Sambamurti

   Target Identification And Validation Pages: 31 - 35

7. The role of the low-density lipoprotein receptor-related protein (LRP1) in alzheimer’s Aβ generation

   • Joy J. Goto
   • Rudolph E. Tanzi

   Target Identification And Validation Pages: 37 - 41

8. Novel glycosaminoglycan precursors as anti-amyloid agents part II

   • Robert Kisilevsky
   • Walter A. Szarek

   Lead Compound Discovery And Optimization Pages: 45 - 50

9. Per-6-substituted β-cyclodextrin libraries inhibit formation of β-amyloid-peptide (Aβ)-derived, soluble oligomers

   • Jiaxin Yu
   • Lara Bakhos
   • Duane L. Venton

   Lead Compound Discovery And Optimization Pages: 51 - 55

10. Novel tricyclic pyrone compounds prevent intracellular APP C99-induced cell death

    • Lee-Way Jin
    • Duy H. Hua
    • George M. Martin

    Lead Compound Discovery And Optimization Pages: 57 - 61

11. Development of a new treatment for alzheimer’s disease and parkinson’s disease using anti-aggregatory β-synuclein-derived peptides

    • Manfred Windisch
    • Birgit Hutter-Paier
    • Eliezer Masliah

    Lead Compound Discovery And Optimization Pages: 63 - 69

12. Using peptide nucleic acids as gene-expression modifiers to reduce β-amyloid levels

    • Beth M. McMahon
    • Jennifer Stewart
    • Elliott Richelson

    Lead Compound Discovery And Optimization Pages: 71 - 76

13. Alzheimer’s disease drug discovery targeted to the APP mRNA 5′Untranslated region

    • Jack T. Rogers
    • Jeffrey D. Randall
    • Steven R. Gullans

    Lead Compound Discovery And Optimization Pages: 77 - 82

14. Continuing strategies for inhibiting alzheimer’s γ-secretase

    • Michael S. Wolfe
    • William P. Esler
    • Chittaranjan Das

    Lead Compound Discovery And Optimization Pages: 83 - 87

15. Discovery of new chemical classes of synthetic ligands that suppress neuroinflammatory responses

    • D. Martin Watterson
    • Jacques Haiech
    • Linda J. Van Eldik

    Lead Compound Discovery And Optimization Pages: 89 - 93

16. Significance and mechanism of alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion

    • Khalid Iqbal
    • Alejandra del C. Alonso
    • Inge Grundke-Iqbal

    Lead Compound Discovery And Optimization Pages: 95 - 99

17. Amyloid peptide toxicity and microtubule-stabilizing drugs

    • Mary L. Michaelis
    • Yingxue Chen
    • Kenneth Audus

    Lead Compound Discovery And Optimization Pages: 101 - 105

18. Alzheimer’s therapeutics

    • Stephen M. Massa
    • Youmei Xie
    • Frank M. Longo

    Lead Compound Discovery And Optimization Pages: 107 - 111

19. Structure-based functional design of chemical ligands for AMPA-subtype glutamate receptors

    • Lei Zeng
    • Luying Lu
    • Ming-Ming Zhou

    Lead Compound Discovery And Optimization Pages: 113 - 116

20. Modulation of axonal regeneration in neurodegenerative disease

    • Stephen M. Strittmatter

    Lead Compound Discovery And Optimization Pages: 117 - 121

21. Towards a high-affinity allosteric enhancer at muscarinic M₁ receptors

    • Sebastian Lazareno
    • Angela Popham
    • Nigel J. M. Birdsall

    Lead Compound Discovery And Optimization Pages: 123 - 127

22. Natural product extracts that reduce accumulation of the alzheimer’s amyloid β peptide

    • Debra Yager
    • Mona Watson
    • Christopher B. Eckman

    Lead Compound Discovery And Optimization Pages: 129 - 133

23. Calpain inhibitors

    • Gabriella Di Rosa
    • Tatjana Odrlijn
    • Ottavio Arancio

    Lead Compound Discovery And Optimization Pages: 135 - 141

24. AF150(S) and AF267B

    • Abraham Fisher
    • Rachel Brandeis
    • Zipora Pittel

    Preclinical Development Pages: 145 - 153

25. Statin therapy for Alzheimer’s disease

    • Suzana S. Petanceska
    • Steven DeRosa
    • Lorenzo M. Refolo

    Preclinical Development Pages: 155 - 161

26. Ovariectomy of young mutant amyloid precursor protein transgenic mice leads to increased mortality

    • Justine A. Levin-Allerhand
    • Jonathan D. Smith

    Preclinical Development Pages: 163 - 166

27. NAP accelerates the performance of normal rats in the water maze

    • Illana Gozes
    • Roy Alcalay
    • Douglas E. Brenneman

    Preclinical Development Pages: 167 - 170

28. CREB and the discovery of cognitive enhancers

    • Roderick Scott
    • Rusiko Bourtchuladze
    • Tim Tully

    Preclinical Development Pages: 171 - 177

29. A computer-assisted cognitive test battery for aged monkeys

    • Jerry J. Buccafusco
    • Alvin V. Terry
    • Paul B. Murdoch

    Preclinical Development Pages: 179 - 185

30. The utility of muscarinic agonists in the treatment of alzheimer’s disease

    • William S. Messer

    Preclinical Development Pages: 187 - 193

31. Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine® CX516 in elderly participants with mild cognitive impairment

    • Steven A. Johnson
    • Vincent F. Simmon

    Clinical Drug Development Pages: 197 - 200

32. Slowing the progression of cognitive decline in alzheimer’s disease using mifepristone

    • Joseph K. Belanoff
    • Jennifer Jurik
    • Alan F. Schatzberg

    Clinical Drug Development Pages: 201 - 206

33. Nerve growth factor gene therapy for alzheimer’s disease

    • Mark H. Tuszynski
    • Leon Thal
    • H. Lee Vahlsing

    Clinical Drug Development Pages: 207 - 207

34. Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated?

    • D. Larry Sparks
    • Donald J. Connor
    • Behalf of the AD Cholesterol-Lowering Treatment Trial Team

    Clinical Drug Development Pages: 209 - 212

35. Development of indole-3-propionic acid (OXIGON™) for alzheimer’s disease

    • Paul E. Bendheim
    • Burkhard Poeggeler
    • Daniel G. Chain

    Clinical Drug Development Pages: 213 - 217

36. Estrogen and cognitive functioning in men with mild cognitive impairment

    • Barbara B. Sherwin

    Clinical Drug Development Pages: 219 - 223

37. Effects of aerobic fitness training on human cortical function

    • Arthur F. Kramer
    • Stanley Colcombe
    • Tracey M. Wszalek

    Prevention: Genetics And Risk Factor Pages: 227 - 231

38. The genetics of exceptional human longevity

    • Thomas Perls
    • Louis M. Kunkel
    • Annibale A. Puca

    Prevention: Genetics And Risk Factor Pages: 233 - 238

39. Genetic and environmental risk factors for alzheimer’s disease in israeli arabs

    • Abdalla Bowirrat
    • Robert P. Friedland
    • Amos Korczyn

    Prevention: Genetics And Risk Factor Pages: 239 - 245